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Summary 
Humoral immunity depends on efficient activation of B-cells and their subsequent differentiation 
to antibody secreting cells (ASCs). Nuclear factor B (NFB) cRel is critical for B-cell proliferation, 
but incorporating its known regulatory interactions into a mathematical model of the ASC 
differentiation circuit leads to the prediction that cRel inhibits ASC generation. Indeed, 
experimental studies revealed that cRel is dynamically repressed during ASC differentiation, and 
that ectopic cRel expression blocks ASC differentiation by inhibiting Blimp1.  Conversely, Blimp1 
inhibits cRel expression by binding the Rel locus. Including this bi-stable circuit of mutual cRel-
Blimp1 antagonism into a multi-scale model revealed that dynamic repression of NFB/cRel 
controls the switch from B-cell proliferation to ASC generation phases and hence the respective 
cell population dynamics.  Our studies provide a mechanistic explanation of how dysregulation of 
this bi-stable circuit may result in pathologic B-cell population phenotypes, and thus offer new 
avenues for diagnostic stratification and treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The production of antibody is key for an effective immune response and efficacy of vaccination. 
Recognition of foreign antigen leads to profound changes within secondary lymphoid organs with 
the formation of the germinal center (GC) and extrafollicular foci that allow for the rapid expansion 
of antigen-specific B-cell clones to produce neutralizing antibody and memory B-cells. Indeed, T-
cell independent (TI) and T-cell dependent (TD) stimulation of B cells generates rapidly 
proliferating cells known as activated B cells (ABCs). ABCs may differentiate into actively cycling 
short lived plasmablasts (PBs), which develop in the early phases of an immune response, and 
quiescent long-lived plasma cells (PCs), which reside in a specialized bone marrow niche. As 
both PBs and PCs are capable of producing antibody, they are referred to as antibody secreting 
cells (ASCs) (Shapiro-Shelef and Calame, 2005). The transition of ABCs to ASCs is coordinated 
by changes in signaling, gene expression and chromatin regulatory networks. ABC-specific 
transcription factors such as Pax5 and Bach2, and ASC-specific transcription factors such as 
Blimp1, regulate distinct genetic programs (Kallies et al., 2007; Nutt et al., 2015). Misregulation 
of these mutually inhibiting transcription factors, caused by common mutations, can result in B 
cell lymphomas with poor prognosis (Mandelbaum et al., 2010; Nutt et al., 2015; Xia et al., 2017). 
Transcription factor NFB is also dysregulated in many B cell lymphomas (Shaffer et al., 2002b) 
and its inhibition is lethal to these transformed cells (Ceribelli et al., 2014; Staudt, 2010).  
 
In ABCs both RelA- and cRel-containing NFB dimers are induced (Kaileh and Sen, 2012). While 
cRel activity is required for cell survival, growth and division during B cell activation (Pohl et al., 
2002; Shokhirev et al., 2015), RelA is required for the generation of GC-derived PCs by 
contributing to Blimp1 activation (Heise et al., 2014). Thus, both cRel and RelA are indispensable 
for humoral immunity but for different functional reasons. However, a recent study showed that in 
the genetic disease B cell expansion with NFB and T Cell Anergy (BENTA), constitutively active 
NFB results in reduced ASC generation (Arjunaraja et al., 2017), suggesting that precise 
regulation of each NFB dimer is required for healthy ASC generation. 
  
Mathematical modeling approaches have proven valuable to understand complex dynamic 
molecular regulatory networks. ABC population expansion dynamics are well accounted for by a 
multi-scale model of the intracellular molecular network of NFB regulating apoptosis and the cell 
cycle (Mitchell et al., 2018; Shokhirev et al., 2015), and this model proved useful in understanding 
the function of cRel in cell survival, growth and division (Shokhirev et al., 2015). In the case of the 
ASC differentiation circuit, the scarcity of quantitative biochemical data first prompted logical 
models that can qualitatively recapitulate the state of regulatory networks in the terminal fates of 
B cells (Mendez and Mendoza, 2016), or a dynamical system of only three regulators (Martinez 
et al., 2012). Larger dynamical models are capable of explaining the distribution of time-spans B 
cells may spend undergoing somatic hypermutation (SHM) prior to terminal differentiation,  but 
either do not include NFB, cRel or RelA (Sciammas et al., 2011), or consider NFB as a single 
regulator without distinct functions of cRel and RelA (Martinez et al., 2012; Mendez and Mendoza, 
2016). 
 
To better understand the role of NFB within the ASC differentiation circuit we extended the work 
of Sciammas et al. by developing a mathematical model of ASC differentiation in which cRel and 
RelA are investigated as distinct regulators. Mathematical modeling, combined with mechanistic 
and functional experimental studies, revealed that cRel must be repressed for ASC differentiation. 
We showed that decreased cRel expression is mediated by Blimp1 through epigenetic remodeling 
of the Rel locus. This insight allowed us to integrate the extended ASC differentiation circuit model 
into our previously established multi-scale model to account for the cell population dynamics of 
ABCs and ASCs in terms of the dynamics of intra-cellular molecular signaling events.  
 
Results 
 
Mathematical modeling predicts that cRel inhibits ASC differentiation  
The previously established ASC differentiation circuit model (Sciammas et al., 2011) includes 
regulatory interactions between transcription factor IRF4, Pax5, Blimp1, Bach2, and Bcl6 (Figure 
1A and 1B): To explore the roles of NFB dimers in ASC differentiation we incorporated RelA and 
cRel and their known subunit-specific regulatory interactions into the ordinary differential equation 
(ODE) model of Sciammas et al.: cRel is known to induce IRF4 (Grumont and Gerondakis, 2000), 
Bach2 (Hunter et al., 2016) and AID activity (Kim and Tian, 2009; Park et al., 2009); RelA induces 
IRF4 (Saito et al., 2007), Blimp1 (Heise et al., 2014; Morgan et al., 2009) and AID (Park et al., 
2009) (Figure 1B, Table S1). The resulting “NFB-extended ASC model v1” contains 7 molecular 
species controlled by 14 regulatory interactions (Figure 1B, Table S2 and Equation S1).   
 
Time-course simulations showed that ASC differentiation trajectories passed through an obligate 
transient state of high AID followed by increased Blimp1 and subsequent AID repression to 
become ASCs (Figure 1C). To interpret model simulations we defined an ASC as a cell that has 
upregulated Blimp1 and downregulated AID (Blimp1>4, consistent with Sciammas et al. and AID 
<4, (Figure S1A)). However, simulations using the NFB-extended ASC model v1 failed to 
produce ASCs in expected numbers (Figure 1C and 1D). AID and Blimp1 upregulation were 
consistent with published results, but increased Blimp1 expression was not followed by the 
obligate AID decrease (Figure 1C and 1D).  At face value, this simulation result suggested that 
either RelA or cRel acts as an inhibitor of ASC differentiation. As RelA is required for ASC 
generation (Heise et al., 2014), we wondered whether decreased cRel expression would allow 
ABCs that had failed to repress AID to complete their differentiation and become ASCs (Figure 
1E). We simulated the effect of decreasing cRel expression (100, 10 or 5 fold) in cells that had 
upregulated Blimp1; the model predicted that decreased cRel expression allows for substantial 
downregulation of AID (Figure 1E, S1B and S1C), enabling the differentiation of ABCs to ASCs 
(Figure 1F). This effect was independent of the thresholds chosen to define an ASC (Figure S1A). 
Thus, math modeling suggested (i) that cRel may be repressed during ASC differentiation, and 
(ii) that this regulatory feature may be necessary for ASC generation.  
 
Transcriptional repression of Rel in ASCs  
To test the first model prediction, ABCs and ASCs were generated ex vivo by stimulating mature 
B cells with the TI stimulus lipopolysaccharide (LPS) (Figure S2A) (Kallies et al., 2007). The 
resulting ASCs showed increased expression of Blimp1 and IRF4, and decreased expression of 
Bach2 compared to ABCs (Figure 2A), confirming that LPS-generated ASCs (defined here as 
LPS-PBs) can recapitulate key regulatory events of in-vivo ASCs and characteristic of PBs 
(Minnich et al., 2016; Nutt et al., 2015; Shapiro-Shelef and Calame, 2005; Shi et al., 2015; 
Tarlinton et al., 2008).  We examined cRel expression by immunoblotting and found that while 
both cRel and RelA expression increased during B cell activation, cRel expression decreased 
3.5 fold in LPS-PBs, whereas RelA remained high (Figure 2A and 2B). The same results were 
observed when PBs were generated with the TD stimulus anti-CD40/IL-4 (defined as CD40-PB) 
(Figure S2B, S3A and S3B) (Kallies et al., 2007).  
 
Analyzing deposited RNA-seq data (Shi et al., 2015), we found that Rel mRNA was lower in 
splenic PBs compared to GC B cells and still lower in splenic PCs and bone marrow PCs (Figure 
S3C). By measuring mRNA with quantitative RT-PCR, we found that Rel expression was 
decreased ~3 fold in LPS-PBs whereas Rela expression remained similar (Figure 2C), and that 
Blimp1 and IRF4 expression were increased whereas Bach2 expression was decreased (Figure 
S3D). This indicated that cRel repression occurred at the transcriptional level. To validate these 
observations in vivo, ASCs and germinal center (GC) B cells were generated by immunization 
with TD antigen (NP-OVA). Lymph node-derived ASCs (LN-ASCs) and GC B cells were purified 
by flow cytometry sorting (Figure S2C and S2D). We found that Rel transcripts were decreased 
20-fold in LN-ASCs compared to GC B cells whereas Rela remained similar (Figure 2D), and 
that Blimp1 and IRF4 were increased, whereas Bach2 was decreased (Figure S3E). We also 
found that cRel expression is decreased in intestinal ASCs (I-ASCs) and these cells show 
elevated Blimp1 compared to other B cells (Figure S3F and S3G). Taken together these data 
suggest that decreased cRel expression may be a general characteristic of PBs and PCs 
irrespective of the nature of stimulation and tissue environment. 
 
Repression of Rel is required for ASC differentiation  
To test the second model prediction that Rel repression is functionally required for ASC 
differentiation, we used the BCL1 cell line, which is capable of stimulus-responsive differentiation 
into ASCs, as evident by gene expression signature (Sciammas and Davis, 2004) and antibody 
production (Lin et al., 1997; Sciammas and Davis, 2004). We found that BCL1 cells stimulated 
with IL-2/IL-5 recapitulated the Rel repression (Figure S4A and S4B) observed in primary B cells 
(Figure 2 and S3). We ectopically expressed cRel in BCL1 cells (BCL1-cRel) which elevated 
Bach2 and diminished Blimp1 proteins (Figure S4B), and increased the proportion of cells in cell 
cycle (Figure S4C). Similarly, Bach2 transcript was increased (~ 2.5 fold) and Blimp1 transcript 
diminished (~ 1.6 fold) (Figure 2E and 2F) indicating transcriptional control. However, ectopic 
expression of cRel also diminished the increase in Blimp1 following stimulation (1.7 fold as 
opposed to 3 fold in controls) (Figure 2F). We also found that BCL1-cRel cells failed to produce 
IgM upon stimulation (Figure 2G) and did not show a substantial reduction in the proportion of 
actively cycling cells (~32% compared to ~35% in unstimulated) (Figure S4C). Thus, ectopic 
expression of cRel appears to block terminal differentiation of B cells.  
 
It has been shown that Bach2-/- B cells have higher Blimp1 and a higher propensity to differentiate 
into ASCs (Muto et al., 2010).  We wondered whether the failure to increase Blimp1 expression 
in BCL1-cRel cells is mediated by Bach2. We deleted Bach2 in BCL1-cRel cells (Figure S4D) 
using CRISPR/Cas9, which reverted Blimp1 expression to the same level as in control BCL1 cells 
(Figure 2H) and allowed for differentiation to ASCs as evident by a rescue of IgM production 
(Figure 2I). We concluded that for ASC differentiation to proceed, Rel must be repressed, so that 
expression of Bach2 can decay, in order to de-repress Blimp1.  
 
Blimp1-mediates transcriptional repression of cRel  
Our computational and experimental studies indicated that decreased cRel expression is required 
for ASC production, we wondered whether Blimp1 may transcriptionally repress Rel.  In “NFB-
extended ASC model v2” (Figure 3A) we tested whether an inhibitory connection between Blimp1 
and cRel production was sufficient to account for ASC generation quantitatively. Indeed, the 
model recapitulated experimental flow cytometry results (Figure 3B and C) within a broad range 
of Blimp1 and AID thresholds used to define ASCs (Figure S5). Thus, the mathematical model 
predicted that Blimp1-mediated repression of Rel may be sufficient to allow ASC differentiation.  
 
To experimentally test whether Blimp1 triggers repression of Rel, we deleted Blimp1 in BCL1 cells 
(Figure S6A) and measured Rel transcripts upon stimulation. Whereas control BCL1 cells showed 
a ~4-fold decrease in Rel expression in response to stimulation with IL-2/IL-5, Blimp1-deleted 
BCL1 cells failed to repress Rel upon stimulation (Figure 4A), while Rela expression remained 
largely unchanged (Figure 4B). Blimp1-deleted BCL1 cells were unable to proceed with ASC 
differentiation, as evident by the lack of IgM production (Figure 4C). Further, analyzing RNA-seq 
data of primary B-cells (Tellier et al., 2016), we found that Blimp1-/- PCs showed increased 
expression of Rel (Figure S6B). This indicated that Blimp1 represses Rel expression as part of its 
program to coordinate ASC differentiation.  
 
To establish whether Blimp1-mediated transcriptional repression of Rel is direct, we examined 
recently deposited Blimp1 ChIP-seq data from PBs (Minnich et al., 2016), and found a prominent 
Blimp1 binding peak in the Rel locus at position 23669376-23670485 in chromosome 11 using 
genome assembly mouse mm9 (Figure 4D). While BCL1 cells showed a ~4-fold transcriptional 
repression of Rel in response to stimuli, CRISPR/Cas9 mediated disruption of a Blimp1 binding 
site in the Rel locus (Figure S6C) substantially reduced this repression (Figure 4E). Rela 
expression remained unchanged in either cell line (Figure 4F). As expected, disruption of Blimp1 
binding sites in the Rel locus rendered BCL1 cells unable to fully proceed with ASC differentiation 
as evident by reduced IgM production (Figure 4G). Thus, we concluded that Blimp1 directly 
represses Rel expression in ASCs. 
 
Next, we sought to characterize the mechanism by which Blimp1 represses Rel transcription. 
Blimp1 is known to interact with histone deacetylases (e.g. HDAC2) and was shown to repress 
transcription by recruiting HDAC to a target promoter (Yu et al., 2000), reducing H3K9 acetylation 
(H3K9ac) abundance (Minnich et al., 2016).  We measured H3K9ac abundance on the Rel locus 
in ABCs and LPS-PBs by ChIP-qPCR, and found a  1.4 ± 0.108% yield in ABCs as opposed to 
 0.4 ± 0.026% yield (relative to input) in LPS-PBs, whereas antibody isotype controls were low 
( 0.05%) and unchanged (Figure S6D). This reduction in H3K9ac by more than 3-fold on the Rel 
locus as ABCs differentiated into LPS-PBs contrasted with unchanged H3K9ac at 1.9 ± 0.1% on 
the Rela locus (Figure S6E). Similarly, analyzing ChIP-seq data (Minnich et al., 2016), showed 
reduced H3K9ac at the Rel locus (Figure S6F). Upon stimulation of BCL1 cells with IL-2/IL-5 we 
found a ~2.6-fold decrease in H3K9ac on the Rel locus in control cells (from 1.7 ± 0.19% to 0.64 
± 0.1%), but no significant change in Blimp1-/- cells (from  1.84 ± 0.19% to 1.8 ± 0.2%) (Figure 
4H). Similarly, mutation of the Blimp1 binding site substantially diminished the loss of H3K9ac 
abundance in response to stimulus (1.45 ± 0.11%) at the Rel locus compared to controls (0.64 
± 0.1%) (Figure 4H), but had no impact at the Rela locus (Figure 4I). Thus, we concluded that the 
differentiation-associated reduction of H3K9ac abundance at the Rel locus is dependent on direct 
binding of Blimp1 and leads to transcriptional repression of Rel in ASCs. 
 
cRel deficiency increases the ASC differentiation propensity but results in a smaller ASC 
population 
To further test the regulatory mechanisms encapsulated in the computational model we simulated 
ASC generation in the absence of cRel and found that the model predicted an increase in ASC 
numbers at time points after 48 hrs (Figure 5A).  This prediction was independent of the threshold 
of Blimp1 and AID chosen to define a cell as an ASC (Figure S7), and consistent with a previous 
report that Rel-/- B cells produce a higher percentage of ASCs after 3 days (Heise et al., 2014). In 
our experiments, we found that while Rel-/- B cells had a substantial proliferative defect and thus 
generated fewer cells overall compared to WT (Figure 5B), the culture contained -1%, -2%, +20% 
and +15% greater proportion of LPS-PBs than WT controls at 24 h, 48 h, 72 h and 96 h 
respectively (Figure 5C, and S8A). By measuring the cell loss associated with cRel-deficiency we 
found that the increased loss in the ABC population from 48 to 72 h (88 to 97%) coincided with a 
decreased loss of LPS-PBs from 48 to 72 h (91 to 86%) (Figure S8B). We also measured cell 
death propensities with Annexin V staining and found that ABCs and LPS-PBs generated from 
Rel-/- B cells showed a similar ~2-fold increase in cell death compared to wild type (Figure S8C 
and S8D). These data suggested that the increased proportion of LPS-PBs vs. ABCs in Rel-/- B 
cells is not due to differential death rates but rather due to an increased propensity to differentiate 
from ABCs into ASCs. These results showed a quantitative agreement with computational 
predictions (Figure 5A), except for the last timepoint, which may reflect a limitation of the in vitro 
culture conditions. 
 To further test the regulatory connections in the model, we generated quantitative predictions of 
the dynamic changes of three critical regulators (Blimp1, Bach2 and IRF4) following stimulation 
of Rel-/- vs. WT B cells. In the mutant, we predicted a 2-fold late-phase increase of Blimp1, a 2-3 
fold reduction in Bach2, and an initial decrease in IRF4 followed by a late-phase increase (Figure 
5D). Experimental quantification by RT-PCR showed a quantitative match to the computational 
prediction with Rel-/- B cells having 2-fold higher expression of Blimp1 in the late-phase, 2-3 fold 
reduced expression of Bach2, and similarly dynamic regulation of IRF4 (Figure 5E and S8E). 
Immunoblots showed similar trends as observed by RT-PCR (Figure 5F). Thus, Rel-/- B cells had 
a higher propensity to differentiate into ASCs through increased expression of Blimp1.   
 
As ASC generation propensity has been shown to increase with cell division (Hasbold et al., 2004) 
we wondered whether Rel-/- B cells have an increased ASC differentiation propensity in a 
generation-specific manner. Cell division was measured by dye dilution assay using Cell Trace 
Red. While both WT and Rel-/- B cells showed increasing ASC generation with each division, Rel-
/- B cells showed a higher proportion of non-dividing (generation ‘0’) cells and an increased 
proportion of LPS-PBs at every generation (Figure 5G and 5H). Thus, Rel-/- B cells showed 
increased ASC differentiation propensities at all generations compared to WT B cells. 
 
Integrating ASC differentiation into a multi-scale B-cell proliferation model reveals how 
cRel dynamics control the dynamics of distinct B-cell populations  
The link between differentiation and division revealed in the WT and Rel-/- B cell experiments 
motivated us to integrate the “NFB-extended ASC model v2” into an established multiscale 
model that accounts for B-cell population dynamics as a result of the molecular network in each 
cell (Mitchell et al., 2018; Shokhirev et al., 2015). By doing this we could discover whether our 
mechanistic understanding was sufficient to explain the effects we observed on differentiation, 
proliferation and the link between the two. This multiscale model includes an NFB module that 
predicts subunit-specific NFB dynamics as a result of the stimulus-induced regulation of multiple 
inhibitors of NFB (IBs). We added NFB’s control over ASC differentiation, as described here 
in “NFB-extended ASC model v2”, to existing NFB-mediated control over the cell cycle and 
apoptosis (Figure 6A). Each cell within this multi-scale model was thus capable of undergoing 
apoptosis, cell-division or differentiation into an ASC (Figure 6B), with cell fate decisions being 
dependent on the particular parameter set sampled from previously determined distributions (see 
Materials & Methods (Mitchell et al., 2018)).  
 A simulation was performed of 200 seeded cells stimulated with LPS. Dynamic changes of cRel 
activation were measured over time as cells within each lineage transition from ABCs (Blimp1low) 
to Blimp1highAIDhigh and subsequently to ASCs (Blimp1highAIDlow). As expected, the model showed 
almost immediate cRel activation and resulting proliferation. Only cells that had increased Blimp1 
expression showed decreased cRel activity with further decreases at later time points as they 
differentiated into ASCs (Figure 6C), while RelA activity remained similar in ABCs and ASCs 
(Figure S9A).  Based on parameter distributions, cells showed heterogeneity in cRel activation 
dynamics and the timing and generation/division number of ASC differentiation (Figure 6C). The 
model predicted that ASCs generated at early timepoints produced a higher percentage of 
proliferating cells compared to those generated at a later time point (Figure 6D and S9B).  
 
To examine the time evolution of molecular markers, and generate an experimentally-testable 
prediction of the multi-scale modeling of signaling, proliferation, apoptosis, and differentiation, we 
tracked cRel and Blimp1 concentrations over time in a population of individually simulated cells 
(Figure 6E, supplemental movie 1). The resulting plot of the cell-population’s path through the 
space of cRel and Blimp1 expression revealed a distinctive trajectory that allowed us to quantify 
specific populations of B-cells based on their cRel and Blimp1 expression (Figure 6F). To test this 
prediction we measured Blimp1 and cRel abundance with single cell resolution through a flow 
cytometry time course and found that B cells first increased cRel expression at 24 hours, with ~ 
70% of cells considered cRel high at 24 and 48 hours (Figure 6G and 6H). Increased cRel 
expression was followed by increased Blimp1 expression with the percentage of Blimp1high cells 
increasing from 20% at 24 hours to 55% at 48 hours and ~80% at 72 and 96 hours. As predicted 
by the model, B cells that showed increased Blimp1 subsequently reduced cRel expression, with 
the percentage of cells with both high Blimp1 and high cRel decreasing from 41% at 48 hrs to 
29% at 72 hrs and 22% at 96 hrs, along with an increase in the population of cells with high Blimp1 
and low cRel from 15% at 48 hrs to 53% at 72 and 96 hrs.  This confirmed the computational 
prediction that proliferation and differentiation dynamics of stimulated B cells are accompanied by 
first high then decreased cRel expression following increased expression of Blimp1 at 72 and 96 
hrs (Figure 6G and 6H).  
 
Multi-scale modeling relates genetic perturbations to physiological or pathological B cell 
population dynamics 
To further investigate the predictive power of the multi-scale model, we examined its ability to 
recapitulate population dynamics of WT and Rel-/- B cells. In the WT condition (Figure 7A left 
panel), the model simulations showed a characteristic transient dip in the total population due to 
death of a proportion of founder cells, before proliferation results in a total population expansion 
that then gives way to a population decline. During the proliferative burst, some cells differentiated 
into ASCs resulting in ASC population dynamics that are distinct but necessarily coordinated with 
the ABC population dynamics.  In the Rel-/- simulation (Figure 7A right panel), the total population 
expansion was dramatically diminished (in agreement with experimental literature, (Kontgen et 
al., 1995; Shokhirev et al., 2015)). While the ASC population was also diminished, their proportion 
of the total was substantially higher, reflecting the enhanced propensity to differentiate (Figure 7A 
and 5B).   By analyzing the simulation data not as a function of time but as a function of generation 
at a single timepoint (72 h), we found that the model predicted that cRel-deficiency results in an 
overall increase in ASC differentiation, which in fact peaks at an earlier generation than in WT 
cells (Figure 7B left panel). The experimental data (Figure 5G) confirmed this prediction (Figure 
7B right panel), though peak ASC proportions appeared one generation later in both genotypes. 
In sum, the multi-scale model appeared to recapitulate key aspects of ABC and ASC population 
dynamics, and the intricate roles of cRel in shaping them. 
 
The concordance between model simulations and experimental observations encouraged us to 
use the multi-scale model as a research tool to explore the consequence of NFB dysregulation 
on B cell population dynamics. Simulations of Blimp1 deficiency resulted in increased Rel 
expression (Figure 7C) and elevated B-cell proliferation (Figure S9C) in line with experimental 
observation  (Calado et al., 2010). Simulation of elevated cRel expression resulted in a dramatic 
increase in the expansion of the ABC population, and a reduction and delay in the generation of 
ASCs, not only proportionally but also in absolute numbers (Figure 7D left panel), reflecting 
experimental observations (Figure 2G). Next, we simulated the effects of disrupting the Blimp1 
binding sites in the Rel locus, which did not substantially alter total ABC cell population dynamics 
but did result in a reduction in the generation of ASCs (Figure 7D, middle panel). This was 
consistent with the reduced antibody production observed experimentally (Figure 4G).  Finally, 
we explored the effect of elevated RelA expression, which led to increased total cell population 
expansion, comparable to elevated cRel simulations. But, in contrast to the elevated cRel 
condition, elevated RelA produced predominantly ASCs (Figure 7D, right panel).  
 
Similar misregulation of the NFB system is associated with different B-cell lymphomas 
originating from distinct phases of the GC reaction (Figure 7E). Germinal Center B-cell like diffuse 
large cell lymphomas (GCB DLBCL) show high cRel cells, and like the cRel high simulations, 
GCB DLBCL cells appear trapped at the stage unable to exit the GC (Rosenwald et al., 2002; 
Shaffer et al., 2002b). Activated B-cell like diffuse large cell lymphomas (ABC-DLBCL) show high 
RelA and moderately high cRel activity with frequent Blimp1 inactivation. As seen in the Blimp1 
deficiency simulation, such cells are trapped at the pre-plasmablast stage i.e. able to initiate but 
unable to complete plasmacytic differentiation  (Davis et al., 2001). In contrast, malignant plasma 
cell disorder multiple myeloma (MM), is characterized by high RelA, and reflecting the highly 
differentiated state of cells in RelA high simulations, MM cells originate from fully differentiated 
plasma cells. The fact that our simulations of conditions of NFB misregulation produced 
analogous in silico phenotypes of population dynamics (Figure 7C) suggests that the multi-scale 
model may be a useful research tool for relating genetic or molecular perturbations to the balance 
of proliferation and differentiation in health and disease. 
 
Discussion 
 
In this work, we developed a quantitative understanding of how NFB dimers control ASC 
differentiation; by iterating experimental and computational modeling work we formulated an 
experimentally-trained kinetic model of B cell proliferation and differentiation which recapitulate 
experimentally observed phenotypes. While cRel activation is critical for B-cell activation, survival 
and ABC population expansion (Pohl et al., 2002; Shokhirev et al., 2015), we report here that its 
repression enables differentiation of ABCs into ASCs. We showed that ectopic expression of cRel 
in B cells prevented Blimp1 expression and consequently impaired ASC differentiation. 
Conversely, Rel-/- B cells showed increased Blimp1 expression and increased propensity for LPS-
PB differentiation, but the LPS-PB population remained diminished suggesting that the reduced 
antigen-specific antibody production (Grumont and Gerondakis, 2000; Heise et al., 2014; Pohl et 
al., 2002) associated with cRel-deficiency is not due to a defect in ASC generation but rather an 
indirect consequence of defective B cell expansion. Thus our study identified cRel dynamics as a 
key determinant of ABC and ASC population dynamics.  
 
Further, we established that Rel repression in ASCs is mediated by Blimp1. Blimp1 is known to 
repress cell growth and proliferation regulators such as Myc and Cyclin E (Lin et al., 2000; Lin et 
al., 1997; Shaffer et al., 2002a); Rel repression may reinforce this regulation as Myc is a cRel 
target gene (Duyao et al., 1990), which was shown to determine the proliferative capacity of ABCs 
(Heinzel and Binh Giang, 2017). A key characteristic of plasma cells is the slowing and cessation 
of the cell cycle and ectopic expression of the cell cycle-promoting regulator (Cyclin E) inhibits 
ASC differentiation (Lin et al., 2000). cRel expression also correlates with proliferative activity 
(Alves et al., 2014; Heinzel and Binh Giang, 2017), and cycling PBs show less cRel 
downregulation than quiescent PCs. Future studies may address to what extent cRel expression 
determines proliferative capacity of ABCs. 
 
Our work points to a mutually antagonistic regulatory logic between cRel and Blimp1, where cRel 
inhibits Blimp1 expression via Bach2 and Blimp1 directly represses cRel expression. Mutual 
inhibition within regulatory networks can result in a bistable system, i.e. a system with two steady 
states (Kaplan and Glass, 2012). Here, one state was characterized by Blimp1lowcRelhigh, and 
another by Blimp1highcRellow. Further, our work suggests that ABCs and ASCs population 
dynamics are governed by how cells dynamically transition through the state space. Stimulation 
of B-cells does not only activate cRel but also RelA, which (directly and through IRF4) promote 
Blimp1 expression; this then allows a portion of cells to build up sufficient Blimp1 to transition to 
the Blimp1highcRellow state and differentiate into ASCs. Thus in the context of B cell proliferation 
and differentiation, cRel and RelA do not compensate for each other (Hoffmann et al., 2003) but 
they have distinct, potentially antagonistic functions.  We posit that the coordinated dynamic 
control of these two NFB family members, and their relative activity over time phase the GC 
reaction of B-cell population expansion, SHM, and ASC generation for an effective immune 
response. 
 
Bistable systems may enforce differentiation decisions so that the differentiated state of the cell 
is maintained even when the differentiating stimulus has decayed (Wang et al., 2009). Healthy 
ASC differentiation is indeed irreversible, and only a significant perturbation of regulatory 
networks, such as the overexpression of Bcl6, may lead to deactivation of the ASC-specific gene 
expression program (Fujita et al., 2004). Although various ASC populations, such as PBs, PCs 
and ASCs from distinct niches show variable Blimp1 and cRel abundances, the mutual 
antagonistic regulation between Blimp1 and cRel may be conserved. Indeed, we found that as 
Blimp1 expression gradually increases from PBs to PCs, there is a concomitant decrease in cRel. 
An inverse correlation between Blimp1 and cRel expression was also observed in intestinal B 
cells and I-ASCs and in human pre-plasma cells exiting from the GC (Cattoretti et al., 2005). 
Nevertheless, the Blimp1 transcriptional repression program may differ in other ways in distinct 
ASC populations; for example, I-ASCs fail to downregulate the Blimp1 target gene CD19 
(Landsverk et al., 2017), and B-cell differentiation during Salmonella infections may involve a 
prolonged Blimp1highAIDhigh state resulting in GC-independent affinity maturation of PBs and 
pathological B cell responses (Di Niro et al., 2015). 
 
Here we presented a mathematical model (NFB-extended ASC model v2), which demonstrated 
that the included gene regulatory interactions are sufficient to explain the differentiation kinetics 
and regulatory dynamics explored here. However, other in vivo or ex vivo experimental conditions 
may involve additional mechanisms. For example, recent results revealed a significant role for the 
complex of IRF8 and PU.1 in the propensity of B cells to undergo CSR and ASC differentiation 
by concurrently promoting the expression of Bcl6 and Pax5 and repressing AID and Blimp1 
(Carotta et al., 2014; Willis et al., 2017). Furthermore, cytokines secreted by T-helper cells are 
known to play important roles in controlling B cell fate in vivo. Thus additional regulatory 
interactions, not represented in the current model, are likely required to account for in vivo 
differentiation, including IL-2 mediated activation of Bcl6 (through Stat5), IL-21 mediated 
activation of Blimp1 (through Stat3) and IL-4 mediated activation of AID (Mendez and Mendoza, 
2016; Tangye, 2014).  
 
The dynamics of cRel are regulated transcriptionally and through dimerization, sequestration by 
IB inhibitors (Almaden et al., 2014; Alves et al., 2014; O'Dea and Hoffmann, 2009), and kinase 
activity (Shinohara et al., 2014). This motivated us to incorporate the NFB-extended ASC model 
v2 into an established multi-scale B-cell model (Mitchell et al., 2018; Shokhirev et al., 2015) that 
explicitly articulates these regulatory mechanisms. The model recapitulated, with single-cell 
resolution, dynamical changes in cRel and Blimp1 expression, cellular proliferation and 
subsequent differentiation of a subset of cells as measured by flow cytometry. Interestingly, the 
model also recapitulated the progression of PBs, generated early in the immune response, with 
still substantial proliferative capacity to terminally differentiated, quiescent PCs generated late in 
the immune response. Thus, the multi-scale model can recapitulate the generation of 
heterogeneous ASC populations, however there are likely further sources of heterogeneity, 
including the splenic architecture’s role in extrafollicular PB and GC-derived PC generation, that 
remain to be investigated experimentally and incorporated into mathematical representations.  
 
The resulting multi-scale model was also capable of recapitulating and disentangling altered 
proliferation and differentiation phases in systems with genetic perturbations in key regulators 
such as cRel, RelA and Blimp1. Thus, the model represents an in-silico laboratory that may be 
used iteratively with wet-lab experiments for mechanistically investigating the variety of B cell 
lymphomas subtypes. Our multi-scale modeing work, supported by quantitative experimental 
data, suggests that coordinated dynamic regulation of cRel and RelA is critical for the switch from 
proliferative to ASC differentiation phases, and perturbations within this network are associated 
with B cell malignancies. Consequently, we suggest that dynamic mis-coordination of cRel and 
RelA may be a more useful concept than hyper- or hypo-activity of generic NFB when addressing 
the mechanisms underlying B-cell lymphoma or humoral response deficiencies.  
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Figure Legend 
Figure 1: Mathematical modeling predicts that cRel prevents ASC differentiation.  
A) Schematic of ASC generation. Stimulation of naïve B cells produces activated B cells (ABCs). 
ABCs either become plasma blasts or undergo class switch recombination (CSR) and somatic 
hypermutation (SHM) before differentiating into plasma cells. Here, plasma blasts and plasma 
cells are defined as antibody secreting cells (ASCs). The regulators and genetic signature that 
characterize each cell type are indicated. B) Schematic of NFB-extended ASC differentiation 
model v1. This model was based on a previously published model from Sciammas et al. 
(Sciammas et al., 2011) to which RelA and cRel were added (see text). Rela- and cRel-mediated 
regulation is indicated in green, genes associated with the CSR/SHM state are shown in violet, 
and genes associated with the ASC state are shown in red. Arrows denote activation, and barred 
lines denote repression. C) The trajectories of Blimp1 and AID expression kinetics in the subset 
of cells that expressed high Blimp1 from a simulation of 125 cells. Four states are defined by two 
coordinate axes, namely Blimp1lowAIDlow (Initiation); Blimp1lowAIDhigh (CSR/ SHM); Blimp1highAIDhi; 
Blimp1highAIDlow (ASC). The final states are in the rectangular boxes below and on right indicating 
Blimp1 and AID expression respectively. Green points show the trajectories and final states of 
the NFB-extended ASC differentiation model v1. Blue points indicate the final state obtained by 
all cells in simulations using a previously published model (Sciammas et al., 2011) D) Kinetics of 
ASC differentiation predicted by the Sciammas et al. ASC differentiation model and the NFB-
extended ASC differentiation model v1. The percentage of ASCs is plotted with time (h). The solid 
line indicates the mean and shaded region indicates the standard deviation of 3 simulations of 
125 cells.  E) The final states (96h) reached by cells expressing high Blimp1 in simulations of 125 
starting cells with the NFB-extended ASC differentiation model v1 (phase 1, green) and a 
subsequent simulation in which cRel activity in those cells was downregulated to 1% and 
trajectories were simulated for 96h (phase 2, red). F) Bar graph of the fraction of ABCs becoming 
ASCs when cRel was allowed to remain at 100% of its expression (phase 1, green) or when it 
was forcibly reduced to 1% of its peak (phase 2, red). Median (black), standard deviation (dark 
green) and standard error mean (light green) are indicated. 
 
  
Figure 2: cRel repression is required for ASC differentiation. A) Immunoblots of Blimp1, IRF4, 
Bach2, cRel (product of Rel gene), RelA and actin in naïve B cells, ABCs and LPS-PBs. ABCs 
and LPS-PBs were generated by stimulating naïve B cells with LPS for 72 h and then isolated by 
flow cytometry (described in Figure S2A). Data shown is representative of three biological 
replicates. B) Quantitative measurements of cRel and Rela immunoblots with actin as loading 
control. C) Quantitative measurements of mRNA expression by qPCR of Rel (encodes cRel 
protein) and Rela in naïve B cells, ABCs and LPS-PBs. D) Quantitative measurements of mRNA 
expression of Rel and Rela in naïve B cells, GC B cells and LN-ASC (Lymph node ASCs). 
Ubiquitin C was used as housekeeping gene to quantitate mRNA expression. E) and F) 
Quantitative measurements of mRNA expression of Bach2 and Blimp1 in unstimulated (Control, 
blank) and stimulated (IL-2+5 24 h, shaded) BCL1 (gray) and cRel-overexpressing BCL1 cells 
(blue, BCL1-cRel). IL-2 and IL-5 (shaded) stimulation is used throughout to differentiate BCL1 
cells to ASC-like states. G) IgM production measured at 96 h by ELISA and expressed in optical 
density (O.D.) units. H) Quantitative measurement of mRNA expression of Blimp1 in unstimulated 
(control, blank) and stimulated (IL-2+5 24 h, shaded) BCL1 (gray), BCL1-cRel (blue), and Bach2-
KO BCL1-cRel (red) cells. I) IgM production measured at 96 h by ELISA and expressed in optical 
density (O.D.) units. In all plots the mean and standard deviation of three replicates is indicated. 
*p < 0.05, **p< 0.01, ***p < 0.001 and not significant (ns) (Unpaired Students t-test). 
 
 
Figure 3: Including Blimp1 inhibition of cRel expression in computational simulations 
enables ASC differentiation. A) Schematic of NFB-extended ASC differentiation model v2, in 
which cRel downregulation was initiated by Blimp1 (grey barred line). B) Percentage ASC 
production over time (h) in simulations with the model v1 (without cRel-Blimp1 inhibition, green, 
Figure 1B) and v2 (with cRel-Blimp1 inhibition, grey, panel A). The solid line indicates the mean 
and shaded region indicates the standard deviation of 3 simulations, each containing 125 founder 
cells. C) Experimental measures of the ASC differentiation kinetics determined by flow cytometry 
at 24 h, 48 h, 72 h and 96 h, with the mean and standard deviation of three replicates indicated. 
 
 
 
 
 
 
 Figure 4: Blimp1 represses Rel expression and diminishes H3K9ac at the Rel locus. 
A) and B) Quantitative mRNA expression by qPCR of Rel and Rela in unstimulated (control, 
blank) and stimulated (IL-2+5 24h, shaded) BCL1 (gray) and Blimp1-/- BCL1 (red) cells. C) IgM 
production measured at 96 h by ELISA and expressed in optical density (O.D.) units. D) Analysis 
of Blimp1 ChIP-seq data in plasmablasts (GSM1843340, Tellier et al., 2016). Blimp1 binding track 
(top); schematic of Rel locus (middle), consensus Blimp1 binding motif indicated in red and 
targeted PAM sequence is underlined (bottom). E) and F) Quantitative mRNA expression of Rel 
and Rela in unstimulated (control, blank) and stimulated (IL-2+5 24 h, shaded) BCL1 (gray) and 
RelBS-mut BCL1 cells (BCL1 cells mutated at the Blimp1 binding site in the Rel locus, blue). G) IgM 
production was measured at 96 h by ELISA and expressed in optical density (O.D.) units. H) and 
I) ChIP-qPCR yield for H3K9ac and IgG (isotype control) at the Rel locus (H) and Rela locus (I) 
in unstimulated (control, blank) and stimulated (IL-2+5 24h, shaded) BCL1 (gray), Blimp1-/- BCL1 
(red) and RelBS-mut BCL1 cells (blue). The yield was calculated with respect to Input. The mean 
and standard deviation of three replicated is shown throughout. *p < 0.05, **p < 0.01, ***p < 0.001 
and not significant (ns) (Unpaired Students t-test). 
 
 
Figure 5: cRel-deficiency enhances ASC differentiation. A) Time-course plot of the 
percentage (%) increase of ASCs in cRel-deficient (Rel-/-) B cells compared to wild type (WT) 
controls as predicted by mathematical modeling using the NFB-extended ASC differentiation 
model v2.  The percentage of LPS-PBs is plotted with time (h). The solid line indicates the mean 
and shaded region indicates the standard deviation of 3 replicates with 125 initial cells. B) Stacked 
area plot indicates experimentally determined absolute cell numbers at 0 h, 24 h, 48 h, 72 h and 
96 h upon stimulation of WT (left) and Rel-/- (right) B cells with LPS. Gray plot indicates total cell 
number (ABCs and LPS-PBs) and the red area indicates the number of LPS-PBs. C) Bar graph 
showing the percentage increase of LPS-PBs in Rel-/- B cells over WT measured by flow cytometry 
from WT and Rel-/- B cells at 24 h, 48 h, 72 h and 96 h. The LPS-PBs percentage is determined 
by B220loCD138+ (described in Figure S8A). The model prediction (panel A) is reproduced as the 
shaded grey region behind the bar graph. D) and E) Blimp1, Bach2 and IRF4 fold change in Rel-
/- B cells compared to WT B cells over time, as predicted by mathematical modeling (left) and 
determined experimentally by qPCR (right). The solid line indicates mean and shaded region 
indicates SD of fold change from three replicates (Y axis) over time (X-axis). No change over WT 
(Fold change = 1) is indicated with a red dashed line. The mean and standard deviation of three 
replicated is shown throughout. F) Representative immunoblots of Blimp1, Bach2, IRF4 and actin 
expression in Rel-/- and WT B cells. Immunoblots were performed at 0 h, 24 h, 36 h, 48 h, 60 h 
and 72 h following stimulation with LPS.  G) Flow Cytometry plot of ASCs (CD138high) and ABCs 
(CD138-/low) at each generation (Cell Trace Red) during LPS-PB production in WT and Rel-/- B cell 
at 48 h and 72 h. Cell division/generation number is indicated at the top of each plot. On 
representative of three replicates is shown.  H) Percentage of LPS-PBs at each generation in WT 
(red) and Rel-/- (black) B cells at 72 h. X-axis indicates generation number and Y-axis indicates 
LPS-PB percentage. The mean and standard deviation of three replicated is shown throughout.  
 
Figure 6: Dynamic cRel repression is initiated by Blimp1 in single cells. A) Schematic of 
multi-scale modeling that determines B cell population fate dynamics with single-cell resolution. 
The multi-scale model is composed of the NFB regulatory network (green box), the apoptosis 
gene regulatory network (grey box), the cell cycle gene regulatory network (blue box) as published 
previously (Mitchell et al., 2018; Shokhirev et al., 2015), and the ASC differentiation network 
(violet and red box) added here. B) Line plots indicate dynamics of NFB, cPARP, Cdh1 and 
Blimp1 in 3 representative cells. Thresholds that trigger fate changes are indicated with red 
dashed lines. Exceeding the threshold of cPARP triggers apoptosis (cell 1), Cdh1 trigger mitosis 
(cell 2 and 3) and Blimp1 triggers differentiation into an ASC (cell 3). Thresholds must be crossed 
in the positive direction. Cell 1 and 2 are founder cells (generation 0) while cell 3 has undergone 
4 divisions (generation 4). C) Line plots of average cRel activity (nuclear cRel:p50 concentration) 
within 200 simulated lineages. Each line represents the average concentration of progeny from a 
single founder cell. ASC generating lineages are indicated as ABCs (blue) transition to 
Blimp1highAIDhigh (pink) and ASCs (red).  X-axis indicates time (h) and Y-axis indicates simulated 
nuclear cRel-p50 heterodimer in nano molar (nM). D) Stacked bar graph of the number of ASCs 
that will not divide (black) and those undergoing at least one division after differentiating (blue). 
Bars are shown for ASCs generated before and after 70 h. E) Blimp1 and cRel expression in a 
population of 1000 single cells simulated with the multi-scale model (panel A) at 0 h, 24 h, 48 h, 
72 h and 96 h. Populations were gated into cRel–Blimp1low (black), cRelhighBlimp1low (blue), 
cRelhighBlimp1+ (violet) and cRellowBlimp1+ (red). Cell numbers are indicated in each quadrant. 
Time points at 15-minute time intervals are shown in supplemental movie 1. F) Stacked bar graph 
of the percentage of cells in each quadrant in the simulation (panel E) at the indicated time points. 
G) Blimp1 and cRel expression measured by flowcytometry with single cell resolution at 0 h, 24 
h, 48 h, 72 h and 96 h. Populations were gated into cRel-Blimp1low (black), cRelhighBlimp1low (blue), 
cRelhighBlimp1+ (violet) and cRellowBlimp1+ (red). The percentage of cells in each gate are 
represent by number in each plot with the respective color code. H) Stacked bar graph of the 
percentage of cells in each gate at the indicated time points (panel G). The mean and standard 
deviation of three replicates are indicated.  
 
Figure 7: Co-ordinated cRel and RelA dynamics control the dynamics of B cell populations. 
A) Area plots from multiscale modelling simulations of 125 WT and Rel-/- cells showing total cell 
number (grey), and ASC populations (Blimp1highAIDlow - red). Each subsequent generation of 
proliferating cells is indicated with a lighter grey. B) Line graphs showing generation-specific cell 
counts of ABCs (black) and ASCs (red) in WT (solid line) and Rel-/- (dashed line) simulations (left) 
and experiment (right, Figure 5G). Cell counts are normalized to the maximum cell count of ABCs 
for each genotype. The shaded region shows the standard deviation of three experimental 
replicates. C) Bar graph of the fold change of cRel expression over WT in wild-type (WT, black), 
Blimp1+/- (maroon) and Blimp1-/- (red) B-cells in simulations and experiment (details of 
experimental data shown in Figure S6B). D) Area plots from multiscale modelling simulations of 
125 cRel High (left), RelBs-mut (middle) and Rela high (right) cells showing total cell number (grey), 
and ASC populations (Blimp1highAIDlow - red). Each subsequent generation of proliferating cells is 
indicated with a lighter grey. E) Illustration of cRel and RelA dynamics during the physiological B 
cell response and their characteristic abundances in B cell malignancies. Upper panel: during B 
cell differentiation naïve B cell produces ABCs, followed by GC B cells/ Extra GC B cells before 
differentiating into PCs. Middle panel: color graph to represent expression of cRel (green) and 
RelA (gray) during the stages of B cell differentiation. Color gradient represents relative 
expression with darker colors indicating higher expression. Lower panel: cRel and RelA 
expression characteristic of indicated B cell malignancies. Their putative cell of origin is indicated 
by aligning with the upper panel. 
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Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Alexander Hoffmann (ahoffmann@ucla.edu). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mice 
Mice were maintained in environmental control facilities at the University of California, Los 
Angeles. Mice of both sexes were littermates and were 10-14 weeks old unless otherwise 
indicated. The Rel-/- (protein name cRel) mice (Kontgen et al., 1995) previously described and 
wild type mice were in C57BL/6 genetic background. The mice were Animal work was performed 
according to University of California, Los Angeles regulations under an approved protocol.  
 
Cell Lines 
HEK 293 (ATCC, CRL-1573) cells were cultured with DMEM, 10% FBS. BCL1 (ATCC, CRL-1669) 
were cultured with RPMI, 10% FBS, 5 mM L-glutamine, and 55 µM 2-Mercaptoethanol. 
 
METHOD DETAILS 
B cell isolation and culture 
Spleens were harvested from 10-12 weeks old female C57BL/6 mice and Rel-/- mice.  
Homogenized splenocytes were incubated with anti-CD43 magnetic beads for 15 min at 4-8ºC, 
washed with MACS buffer (Phosphate buffer saline, (pH 7.4), 0.5% bovine serum albumin and 2 
mM Ethylenediaminetetraacetic acid (pH 8)) and passed through LS column (Miltenyi Biotech). 
The purity of B cells was >95% based on B220 staining as described previously (Mitchell et al., 
2018). Briefly, the enriched B cell population was stained with B220-eF450, CD3e-FITC, CD11b-
FITC and Ly-6C-Alexa 488. The stained cells were gated on B220+CD3e-CD11b-Ly-6C-. 
B cells were grown in fresh media with 1% penicillin streptomycin solution, 5 mM L-glutamine, 20 
mM HEPES buffer, 1mM MEM non-essential amino acid, 1 mM Sodium pyruvate, 10% FBS, and 
55 µM 2-Mercaptoethanol.   
 
Sorting of B cells subtypes by flow cytometry 
Mature splenic B cells were plated in a 10 cm petri-dish and treated with LPS (10 g/mL) for 72 h 
in 10 mL media with 1x106 cells/mL. Cells were harvested and resuspended in 100 L of cold 
media. Nonspecific binding was blocked with Fc receptor blocker by incubating for 10 min on ice 
and stained with B220-eF450 and CD138-APC in a total of 200 L of cold media for 30 min in ice. 
The excess antibody was removed and washed by centrifugation at 500 rcf, 4ºC for 3 min, and 
then tubes were turned 180° and centrifugation was repeated. Cells were resuspended in media 
and dead cells were excluded using 7AAD. ABCs (B220hiCD138-) and ASCs (B220lowCD138+) 
were sorted based on expression of B220 and CD138 by flow cytometer (Figure S2A).  
Inguinal lymph nodes were isolated from immunized mice. GC B cells were sorted at 7 days after 
primary immunization. Homogenized lymph nodes were incubated with Fc receptor blocker for 10 
min in ice and stained with B220-eF450, CD3e-FITC, CD11b-FITC, CD11c-FITC, CD49b-FITC, 
FAS-APC and CD38-PE in a total of 100 L of cold media for 30 min in ice. GC B cell were sorted 
using the gating strategy B220+CD38-FAS+ (Figure S2C). ASCs were isolated from lymph nodes 
7 days after a booster dose of immunization. Homogenized lymph nodes were incubated with Fc 
receptor blocker for 10 min in ice and stained with B220-eF450, CD3e-FITC, CD11b-FITC, 
CD11c-FITC, CD49b-FITC and CD138-APC in total 100 L of cold media for 30 min in ice. ASCs 
were sorted using gating strategy B220lowCD138+ (Figure S2D). 
 
Mouse immunization  
10-12 weeks old female C57BL/6 mice were immunized with 100 g of NP-OVA emulsified in 
Complete Freund Adjuvant in the foot pad, followed by an equivalent booster shot after 21 days.  
 
Isolation and characterization of intestinal ASC 
Isolation of murine lymphocytes from the small-intestinal lamina propria was performed as 
previously described (Couter and Surana, 2016). Briefly, resected small-intestinal segments were 
washed, inverted, and the epithelial fraction was removed by incubating for 15 min at 37°C in 
RPMI with 5 mM DTT, 1 mM EDTA, and 2% FBS. The residual fraction was minced and digested 
for 30 min at 37°C in RPMI with collagenase II (1.5 mg/ml), dispase (0.5 mg/ml), and 1% FBS. 
Lamina propria single-cell suspensions were obtained by passing through 100 uM and 40 uM cell 
strainers, and resuspended in RPMI containing 2% FBS. Homogenized cells were incubated with 
fixable viability dye eF506 (Affymetrix Bioscience, #65-0866-18) in total 1 mL PBS for 30 min on 
ice and washed with PBS. Cells were then incubated with Fc receptor blocker for 10 min in ice 
and stained with B220-APC-Cy7, CD3e-FITC, CD11b-FITC, CD11c-FITC, CD49b-FITC, Ly-6G-
FITC and CD138-PerCP Cy5.5 in total 100 L of cold media for 30 min in ice. The gating strategy 
is similar to lymph node ASCs. B cells and ASCs were characterized using B220+ and B220-
CD138+ respectively. 
 
Genetic modification of BCL1 cells 
To lentivirally transduce BCL1 cells, HEK 293 cells were transfected with all lentivirus constructs 
using lipofectamine (Invitrogen). 48 h post transfection, virus was harvested and used to infect 
murine BCL1 cells in the presence of polybrene (7.5 µg/ml). Lentivirally infected BCL1 cells were 
grown in the presence of puromycin for 3 days (Yoon and Boss, 2010). Plasmids used: pLX-cRel, 
Bach2-/- guide RNA (5’-CACCGGAACTTTCGTCCCCCTGCGC-3’ and 5’-
CACCGTGCTGCAGGGACGGGCACAA-3’) and Blimp1-/- guide RNA (5’-
CACCGGAATCCAGCTCACTCTGCCC-3’ and 5’-CACCGACCTGGCTGCCTGTCAGAAC -3’) 
cloned in the LentiV2 plasmid. The efficiency of knock in and knock out was assessed by 
immunoblot as indicated. 
Electroporation of BCL1 cells was performed as described previously (Lin et al., 2000; Lin et al., 
1997) with some modifications. Briefly, 2 x105 cells were plated and washed with PBS (without 
Ca2+ and Mg2+). Cells were resuspended in Resuspension Buffer R at 2x105 cells/10 L and 1 
g of plasmid DNA was added. Cells were gently pipetted to obtain a single cell suspension. Cells 
were electroporated in Neon Transfection systems (Invitrogen) and plated in 6 well plates. A pulse 
voltage of 1000 mW and width of 40 ms was used for electroporation. Electroporated cells were 
grown in the presence of puromycin for 3 days. Blimp1 binding site disruption (RelBS-mut) was 
performed using guide RNA (5’-CACCGTACTAGAGCATCTGAAAGCC-3’) cloned in the Lentiv2 
plasmid. The efficiency of mutation was measured by Next Generation Sequencing. The targeted 
genomic region was PCR amplified (using the primer: ACTTAAAGCCTTTTTGTGCTTCT and 
CAGTTTCCTTTACAGCAGGAGTT) and PCR products were gel purified. The purified PCR 
products were submitted for amplicon-EZ (150-500 bp) sequencing (Genewiz). Adapter-trimmed 
sequencing results were processed for quality control using FASTX-Toolkit. A Python script was 
then used to analyze counts of unique mutated or wild type amplicons (code is available as 
Supplemental File 1). Piechart was plotted with Graphpad Prism (Figure S6C).  
 
RNA and Immunoblot Analysis  
For qPCR, mRNA was isolated from B cells, ABCs, ASCs, 10 g/ml LPS-stimulated wild-type and 
Rel-/- B cells following 24, 36, 38, 60 and 72 hours of culture and BCL1 cells following stimulation 
with IL-2 (20 ng/ml) and IL-5 (20 ng/ml), using the Zymo Research kit. 1 g mRNA was used to 
prepare cDNA using Oligo (dT) and quantitation was performed using the SSO syber green. 
Expression was normalized using ubiquitin C as a housekeeping gene. The primers used in this 
study are specified in Table S3. 
For Immunoblot analysis, whole-cell lysates were prepared using RIPA lysis buffer. The resulting 
lysates were run on either 10% SDS-PAGE gels or 5–14% Criterion Tris-HCl Gel (Bio-Rad). The 
following antibodies were used to identify the protein of interest: Rela, cRel, Blimp1, IRF4, Bach2 
and actin (all from Santa Cruz Biotechnology). The resulting proteins were detected using the Bio-
Rad ChemiDoc XRS System and SuperSignal West Femto Substrate Maximum Sensitivity 
Substrate (Thermo Scientific) to detect chemiluminescence released by HRP-labeled secondary 
antibodies. 
 
IgM production measurement by ELISA 
For ELISA analysis, BCL1 and genetically modified BCL1 cells were plated in a 48 well plate with 
2x105 cells/well in a 250 l volume. The cells were stimulated with IL-2 (20 ng/ml) and IL-5 (20 
ng/ml) for 96 hr and the supernatant was collected. The resulting supernatant was tested to 
measure secreted IgM by ELISA. ELISA was performed using mouse Ig isotyping ELISA kit 
according to manufacturer protocol. 
 
Chromatin Immunoprecipitation (ChIP) 
For ChIP experiments 10x106 cells were washed with 10 ml PBS at room temperature (RT) and 
fixed with freshly supplemented 1% methanol-free formaldehyde and incubated at RT for 10-15 
min with gentle shaking. The fixation reaction was quenched with 500 mM Tris pH 8 for 2-5 min. 
The cells were washed twice with cold PBS followed by snap freezing with dry ice. The cell pellets 
were thawed and resuspended on ice in 1 ml Lysis Buffer 1 and incubated on a nutator at 4°C for 
10 min before centrifugation at 800 rcf, 5 min, 4°C; supernatant was then discarded. Similar steps 
were performed with 1 ml Lysis Buffer 2. The nuclei were resuspended in 0.5 ml Lysis Buffer 3 
Plus and incubated on ice for 10 min. The lysates were transferred into 1.5-ml TPX tubes 
(Diagenode #C30010010-1000, min 100 μl-max 300 μl/tube) and sonicated with a Bioruptor water 
bath sonicator using 25 cycles consisting of 30 sec ON/30 sec OFF at low intensity, 4°C. 
Sonication was stopped every 5 cycles for incubation on ice for 1 min, gentle inversion and pulse-
spin. Aliquots were consolidated with the same sample into a single 1.5-ml polypropelene tube. 
The lysate was centrifuged at max speed for 15 min at 4°C. The supernatants were transferred 
to 1.5-ml no-stick microtubes (Phenix Research #MH-815S) and 3 volumes of dilution buffer were 
added to lysates. Unconjugated beads (25 μl/ml of diluted lysate) were washed (twice with PBS 
and dilution buffer) and dried up in no-stick tubes using a magnet. Lysates were mixed with dry 
beads and incubated for 2 hrs at 4°C on a nutator. Lysates were used for the next step and beads 
were discarded. 1% aliquots were taken as input and stored at 4°C with volumes noted.  2 μg 
anti-H3K9ac antibody and isotype IgG were incubated with the lysate overnight at 4°C on a 
nutator. 25 μl protein G-conjugated magnetic beads (Active Motif #53014) were washed twice 
with Dilution Buffer, then once with low-salt buffer. Beads were dried using a magnetic rack. 
Lysates were transferred to dry beads and incubated for 5 hrs at 4°C on a nutator. Beads were 
collected using a magnetic stand and washed twice with each of the following ice-cold buffers in 
order: low salt, high salt, LiCl, TE. 600 μl of buffer was used in each wash step and beads were 
resuspended by inversion, and placed in a high-speed shaker at RT for 5 min. Beads were 
resuspended in 70 μl of 250 mM NaCl. Input fractions were recovered and volumes were adjusted 
to 70 μl with 250 mM final concentration of NaCl. Both input and IP fractions were processed in a 
similar way after this. 50 μg DNAse-free RNAse A (Roche #11119915001) was added and 
incubated at 37°C for 1 hr with gentle mixing. SDS was added for a 1% final concentration and 
then 50 μg Proteinase K (Roche # 03115828001) was added for an overnight incubation at 60°C 
with gentle shaking. SPRI beads were resuspended by gentle vortexing, allowed to warm to RT 
and the supernatant was removed from Protein G beads.  Protein G beads were washed with an 
additional 30 μl of 500 mM NaCl and combined with the first eluate. 0.9-1.0 volumes of SPRI 
beads were added and incubated at RT for 15 minutes on a nutator. Beads were collected using 
a magnetic stand and supernatants were removed. Beads were twice washed with 80% ethanol 
and residual ethanol from tubes was removed by air-drying beads for 5 minutes. DNA was eluted 
from beads with 30 μl TE buffer. Enrichment of the targeted DNA in the elution was measured by 
qPCR and the enrichment was calculated with respect to input. 
 
Buffer composition:  
Lysis Buffer 1: 50 mM HEPES-KOH, pH 7.6, 140 mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% 
NP-40, 0.25% Triton X-100, EDTA-free protease inhibitors. 
Lysis Buffer 2: 10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, EDTA-free 
protease inhibitors. 
Lysis Buffer 3: 10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na 
Deoxycholate, 0.5% N-lauroylsarcosine, sodium salt (Sigma-Aldrich #61739), EDTA-free 
protease inhibitors. 
Dilution Buffer: 10 mM Tris-HCl, pH 8.0, 160 mM NaCl, 1 mM EDTA, 0.01% SDS, 1.2% Triton X-
100, EDTA-free protease inhibitors. 
Low Salt Wash Buffer: 50 mM HEPES-KOH, pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% Triton X-
100, 0.1% Na Deoxycholate, 0.1% SDS, EDTA-free protease inhibitors. 
High Salt Wash Buffer: 50 mM HEPES-KOH, pH 7.6, 500 mM NaCl, 1 mM EDTA, 1% Triton X-
100, 0.1% Na Deoxycholate, 0.1% SDS. 
LiCl Buffer: 20 mM Tris-HCl, pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% Na Deoxycholate, 0.5% 
NP-40. 
TE Buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) 
 
Measurement of apoptotic cells in ABC and LPS-PB 
WT and Rel-/- B cells were treated with LPS (10 g/mL) for 72 h as described above. Cells were 
harvested and resuspended in 100 L of cold media. Nonspecific binding was blocked with Fc 
receptor blocker by incubating for 10 min on ice and stained with B220-PE and CD138-APC in a 
total of 200 L of cold media for 30 min in ice. Stained cells were washed with FACS buffer (PBS 
with 5% FBS) and resuspended in Annexin V binding buffer. The staining of Annexin V Alexa 
Fluor™ 488 and Propidium Iodide (PI) was performed using Dead Cell Apoptosis Kit 
(ThermoFisher Scientific, # V13241) as described by manufacturer protocol. Briefly, 5 μL Alexa 
Fluor™ 488 annexin V and 1 μL PI (100 μg/mL PI working solution) were added to 100 μL of cell 
suspension. The cells were incubated at room temperature for 15 minutes. 400 μL annexin-
binding buffer was added, mixed gently, and the samples were acquired in BD LSRFortessa™ 
flow cytometry (BD Bioscience). Data were analyzed with FlowJo. The gating strategy and ABC 
and LPS-PBs were characterized by as described above. ABC and LPS-PBs population were 
gated for Annexin V and PI positivity. The apoptotic cells were defined as AnnexinV+PI- (Figure 
S8C).   
 
Measurement of generation-specific ASC 
WT and Rel-/- B cells stained with Cell Trace Far Red (CTR) using CellTrace™ Far Red Cell 
Proliferation Kit (ThermoFisher Scientific, # C34564) as described by the manufacturer protocol. 
Briefly, cells were resuspended in 1 mL RT PBS and incubated with 1 L CTR for 25 min at RT 
with rotation. Cells were washed followed by resuspension in RPMI with 10% FBS and incubated 
for 10 min at RT. The cells were washed and washing steps were repeated 1 more time.  CTR 
labeled cells were treated with LPS (10 g/mL) for 24 h, 48 h, 72 h and 96 h as described above. 
The cells were harvested at indicated time points, stained for CD138 and 7AAD as described 
above. The cells were acquired in CytoFlex flow cytometer. Dead (7AAD+) cells were exclude 
from the analysis and the data were analyzed in FlowJo. Cell generation number was defined 
based on dilution of CTR and ASCs were defined by expression of CD138. The generation 
specific percentage of ASC were calculated using the equation:  
Proportion ASC in generation (n) =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐴𝑆𝐶 𝑖𝑛 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛)
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛) 
 
For each generation, n. 
 
Intracellular staining 
Naïve mature B cells (B cells) were isolated from spleens as described above. Cells were treated 
with LPS (10 g/mL) in 12 well plates (5x105/well) for 0, 24, 48, 72 and 96 hours. Cells were 
washed twice with PBS, followed by permeabilization and staining with primary antibody and then 
secondary antibody using Fix and Perm cell permeabilization kit (ThermoFisher, # GAS003). Cell 
permeabilization and staining protocol as described by the manufacturer was followed. Cells were 
stained with cRel-PE and Blimp1-Alexa 647 antibody to measure expression of cRel and Blimp1 
respectively by flowcytometry.  
B cells were treated with anti-CD40 antibody (10 g/ml) and IL-4 (5 ng/ml) for 72 h and stained 
for ABCs and CD40-PB as described above. Intracellular expression of cRel and Rela was 
measured using cRel-eF660 and Rela-PE respectively by flowcytometry using CytoFlex flow 
cytometry (488nm 50mW laser) (Beckman Coulter) and data were analyzed with FlowJo. 
Intestinal lymphocytes were isolated and characterized as described above. Intracellular 
expression of cRel and Blimp1 was measured using cRel-PE and Blimp1-Alexa 647 respectively 
by BD LSRFortessa™ flow cytometry (BD Bioscience) and data were analyzed with FlowJo. 
 
Cell Cycle Analysis 
BCL1 and BCL1-cRel cells were plated in a 35 mm petri-dish with 1x106 cells in a 2 ml volume. 
The cells were stimulated with IL-2 (20 ng/ml) and IL-5 (20 ng/ml) for 24 hr. The cells were 
harvested and washed with cold PBS. The cell pellets were fixed by drop wise addition of 70% 
cold ethanol with continuous mild vortex and cells were kept overnight (16-20 hr) at 4°C. The cells 
were washed with PBS twice by centrifugation 850 rcf for 5 min at 4°C and turned the tube 180° 
to repeat centrifugation. Cells were treated with 50 µl of a 100 µg/ml sock of RNase A for 15 min 
at 37°C and 200 µl of propidium iodide (PI) from 50 µg/ml stock solution were incubated for 15 
min at RT.   
The cells were acquired in flow cytometer (CytoFLEX, Beckman Coulter). The cells were gated 
based on forward scattered (FSC) and side scattered to identify single cells. Doublet were 
excluded from analysis using FSC area and FSC width. The DNA content was measured by 
staining with PI.  
 
Computational Modeling of ASC Differentiation  
Computational modeling was performed in MATLAB by re-constructing the system of ODEs, with 
identical parameters and reactions as described by Sciammas et al. (2011). ODE solver ODE45 
was used throughout. To construct the NFB-extended ASC model v1, cRel and RelA were 
included with two additional differential equations. Additional reactions were included as shown 
in Figure 1B and 3A with similar kinetic rate laws. Briefly, degradation was mass action with Hill 
equations used for activation and inhibition. Parameters and thresholds were chosen to be 
consistent with Sciammas et al. and maintained the same throughout (Sciammas et al., 2011). All 
equations, parameters and initial conditions are given in the Supplemental modeling 
methodology. While the previously published model sampled IRF4 activation rates to simulate 
cell-to-cell variability of activation strength, here we sampled cRel and Rela activation rates with 
the same coefficient of variation (0.4) as used for IRF4 in Sciammas et al. 
cRel downregulation (Figure 1) was investigated by running a timecourse simulation of 125 
individual cells for 96 hours then taking the final molecular abundances as an initial condition of 
a subsequent 96 hour simulation in which cRel expression was reduced as indicated. 
To construct the NFB-extended ASC model v2, Blimp1-mediated cRel downregulation was 
incorporated through hill kinetics consisted with the NFB-extended ASC model model v1. 
Constant cRel expression (𝑒𝑐 = 1) was replaced with: 
𝑐𝑅𝑒𝑙𝑒𝑥𝑝 = 𝑒𝑐 ∙ (
𝐾𝑟
𝑛𝑟  
𝐾𝑟
𝑛𝑟 + [𝐵𝐿𝐼𝑀𝑃]𝑛𝑟
). 
To simulate Rel-/- we set cRel expression to 0 and simulated a population of 125 individual cells. 
ASC generation in cRel deficiency is controlled by RelA, RT-PCR analysis showed that Rel-/- B 
cells reduced RelA expression at 24 h (20-40%) and had very similar expression at 72 h compared 
to wild type. This was incorporated into our Rel-/- simulations through reducing RelA expression 
rate (40% of WT) up to 24h and returning this rate to near WT (70% of WT) for the remaining 
simulation time. 
 
Multiscale Modeling 
The NFB-extended ASC model v2 constructed here was combined with a published model of B-
cell proliferation (Mitchell et al., 2018) to create a multiscale model capable of simulating the 
division, death and differentiation of a population of individual cells. All reactions and parameters 
within the differentiation networks were maintained as described here and all reactions and 
parameters within the NFκB, apoptosis and mitosis networks were maintained as described by 
Mitchell et al. (Mitchell et al., 2018). NFκB activation sampling as described above for NFB-
extended ASC model v1 and v2 was not performed here as cell-to-cell variability was quantified 
in Mitchell et al. and simulated here in the same manner resulting in realistically distributed NFκB 
activities. As the absolute concentration of cRel in the differentiation model and multiscale model 
differed  (due to the arbitrary concentrations of molecular species in the previously published 
differentiation model (Sciammas et al., 2011)) the KD of cRel- and Rela-mediated reactions in the 
differentiation network were scaled to be approximately half the maximum cRel and Rela 
concentrations observed in simulations from Mitchell et al. A population of 1000 single cells was 
simulated and scatter plots of cRel vs Blimp1 were created every 15 minutes for 124 hours 
(Supplemental Movie 1 and Figure 6E). Rel-/- simulations were performed by removing cRel 
expression and reducing RelA expression as described for the ASC differentiation model. A 
similar approach was taken to Blimp1, with Blimp1-/- simulated by scaling Blimp1 expression by 
50%. RelBS-seq cells were simulated by removing terms representing Blimp1 inhibition of cRel 
expression from the ODE for cRel. cRel-High simulations were performed by increasing cRel 
expression 5-fold. All code is available at http://www.signalingsystems.ucla.edu/models-and-
code/. 
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Details of the statistical tests applied to replicates of datasets shown in Figures can be found in 
the corresponding Figure legends. Statistical analyses were performed using GraphPad Prism 7 
software. *p < 0.05, **p < 0.01, ***p < 0.001 and not significant (ns) (Unpaired Students t-test). 
 
DATA AND SOFTWARE AVAILABILITY 
The analysis tool of CRISPR mutation efficiency is available as python code in Supplemental file 
1. The three mathematical models presented in this manuscript, namely NFkB-extended model 
v1, NFkB-extended model v2, and Multi-scale B-cell model are available as matlab code 
at http://www.signalingsystems.ucla.edu/models-and-code/. 
 
 
KEY RESOURCES TABLE 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rat Monoclonal anti-mouse CD16/32 (Fc receptor 
blocker) 
BioLegend Cat#101302 
Rat monoclonal anti-B220-eF450   eBioscience Cat#48-0452-82 
Rat monoclonal anti-human/mouse B220-PE   eBioscience Cat#12-0452-83 
Rat monoclonal anti-mouse/human B220-FITC   BioLegend Cat#103206 
Rat monoclonal anti-mouse/human B220-APC-Cy7 BioLegend Cat#103223 
Armenian hamster monoclonal anti-mouse CD3e-
FITC 
eBioscience Cat#11-0031-82 
Rat monoclonal anti-mouse CD11b-FITC   eBioscience Cat#11-0112-82 
Rat monoclonal anti-mouse Ly-6C-Alexa 488 eBioscience Cat#53-5932-82 
Armenian hamster monoclonal anti-mouse CD11c-
FITC 
eBioscience Cat#11-0114-82 
Rat monoclonal anti-mouse CD49b-FITC eBioscience Cat#11-5971-82 
Mouse monoclonal anti-mouse FAS-APC   BioLegend Cat#152604 
Rat monoclonal anti-mouse CD38-PE   BioLegend Cat#102708 
Rat monoclonal anti-mouse CD138-PE BioLegend Cat#142504 
Rat monoclonal anti-mouse CD138-PerCP Cy5.5 BioLegend Cat#142509 
Rat monoclonal anti-mouse CD138-APC   BioLegend Cat#142506 
Rat monoclonal anti-mouse CD138-Biotin   BioLegend Cat#142511 
Rat monoclonal anti-mouse Ly-6G-FITC   BioLegend Cat#127605 
Rat monoclonal anti-mouse Blimp1-Alexa 647 BioLegend Cat#150003 
Rat monoclonal anti-mouse cRel- PE   eBioscience Cat#12-6111-80 
Rat monoclonal anti-mouse cRel-eF660 eBioscience Cat#50-6111-80 
Mouse monoclonal anti-Rela-PE   Cell Signaling Cat#9460 
Rabbit polyclonal anti-Rela   SantaCruz Cat#sc-372 
Rabbit polyclonal anti-cRel   SantaCruz Cat#sc-71 
Rat monoclonal anti-Blimp1   SantaCruz Cat#sc-47732 
Goat polyclonal anti-IRF4   SantaCruz Cat#sc-6059 
Rabbit polyclonal anti-Bach2   Abcam Cat#ab83364 
Goat polyclonal anti-Actin   SantaCruz Cat#sc-1615 
Rabbit polyclonal Anti-Histone H3  (acetyl K9)   Abcam Cat#ab4441 
Rabbit isotype IgG   SantaCruz Cat#sc-2027 
Chemicals, Peptides, and Recombinant Proteins 
fixable viability dye eF506 Affymetrix 
Bioscience 
Cat#65-0866-18 
7 aminoacitomycine D (7AAD) BioLegend Cat#420404 
Critical Commercial Assays 
Ig isotyping ELISA kit eBioscience Cat#88-50630-88 
Dead Cell Apoptosis Kit ThermoFisher 
Scientific 
Cat# V13241 
CellTrace™ Far Red Cell Proliferation Kit ThermoFisher 
Scientific 
Cat#C34564 
Fix and Perm cell permeabilization kit ThermoFisher 
Scientific 
Cat#GAS003 
   
Deposited Data 
Analyzed the deposited data Nature Immunology, 
2015,16(6):663-73 
GSE60927 
Analyzed the deposited data Nature Immunology, 
2016,17, 323–330  
GSE70981 
Analyzed the deposited data Nature Immunology, 
2016, 17, 331–343  
GSE71698 
Experimental Models: Cell Lines 
HEK 293 ATCC CRL-1573 
BCL1 ATCC CRL-1669 
   
Experimental Models: Organisms/Strains 
Mouse: C57BL/6 The Jackson 
Laboratory 
JAX: 006494 
Mouse: C57BL/6: rel-/-  Kontgen et al., 1995, 
Genes & 
development 9, 
1965-1977 
N/A 
   
Oligonucleotides 
pLX-cRel, Bach2 KO guide RNA (5’-
CACCGGAACTTTCGTCCCCCTGCGC-3’, 5’-
CACCGTGCTGCAGGGACGGGCACAA-3’) 
This paper N/A 
Blimp1 KO guide RNA (5’-
CACCGGAATCCAGCTCACTCTGCCC-3’, 5’-
CACCGACCTGGCTGCCTGTCAGAAC -3’) 
This paper N/A 
Blimp1 binding site disruption guide RNA (5’-
CACCGTACTAGAGCATCTGAAAGCC-3’) 
This paper N/A 
Blimp1 PCR primer: 
ACTTAAAGCCTTTTTGTGCTTCT and 
CAGTTTCCTTTACAGCAGGAGTT 
This paper N/A 
Software and Algorithms 
Graphpad Prism  GraphPad Software  
Mathworks MATLAB MathWorks, Inc R2014a 
Other 
All Computational Modeling Code 
 
This paper http://www.signalin
gsystems.ucla.edu
/models-and-code/ 
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Figure S1: cRel downregulation enables ASC production in simulations regardless of the 
AID threshold used to define an ASC. A) Percentage of cells with Blimp1>4 and AID<4 
(representing ASCs) after an initial (phase 1) simulation with the NFB-extended model v1 and 
subsequent (phase 2) simulation in which cRel is downregulated to 1%. Each point indicates the 
final ASC percentage in 125 cells after 96 hours. B) and C) Bar graph of ASC percentage 
generated in phase 2 simulations with 10 fold (left) and 5 fold (right) cRel downregulation 
respectively. Median (black), standard deviation (dark green) and standard error mean (light 
green) are indicated. 
Supplemental Figures and Table Click here to access/download;Supplemental Text and
Figures;Supplemental Information.docx
  
Figure S2: Gating strategy and purity of fluorescence-activated-cell-sorted cells. A) Gating 
strategy and flow cytometry plot showing purity of ex-vivo generated ABCs and LPS-PBs upon 
stimulation with LPS. ABCs and LPS-PBs were determined by B220lowCD138+ and B220+CD138-
. Cell percentage of ABCs (60.5%) and LPS-PBs (11.5%). Purity of ABCs (97.9%) and LPS-PBs 
(94.2%). B) Gating strategy and flow cytometry plot of ABCs and CD40-PBs upon stimulation with 
anti-CD40 antibody and IL-4. C) Gating strategy and flow cytometry plot showing purity of 
fluorescence-activated-cell-sorted GC B cells as determined by B220+FAS+CD38-. Cell 
percentage of GC B cells in the B220+ lymph node cells (1.82%) and purity of GC B cells (99%). 
D) Gating strategy and flow cytometry plot showing purity of fluorescence-activated-cell-sorted 
ASCs as determined by B220lowCD138+. Cell percentage of LN-ASCs in B220high,low lymph node 
cells (8.78%) and purity of ASCs (95.8%). 
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Figure S3: cRel and RelA expression in ABCs and ASCs. A) Histograms of cRel (left) and 
RelA (right) expression in B cells (black), ABCs (blue) and plasmablast (green, CD40-PB) upon 
stimulation with anti-CD40 antibody and IL-4. cRel and RelA expression was measured by 
intracellular staining followed by flow cytometry and X-axis indicates the fluorescence intensity. 
B) Bar graph of relative mean fluorescence intensity (MFI) of cRel and RelA, relative to naïve B 
cells (1). C) Bar graph of Rel expression (RPKM) in Follicular B cells (FoB), B1 B cells (B1), 
Marginal Zone B cells (MZB), Germinal Center B cells (GCB), Splenic Plasmablasts (SplPB), 
Splenic Plasma Cells (SplPC), Bone Marrow Plasma Cells (BMPC), LPS stimulated B cells (LPS-
B), Plasmablasts generated upon LPS stimulation (LPS-PB), CD40+ IL4 stimulated B cells 
(CD40-B) and Plasmablast generated upon CD40+IL4 stimulation (CD40-PB). Inset: zoomed 
view of Rel expression in SplPB, SplPC and BMPC. The data were analyzed using deposited 
RNA_Seq data (accession number is GSE60927) by Shi et al, (2015). The number of replicates 
in the bar graph depends on available dataset. D) Bar graph of mRNA expression by pPCR of 
Blimp1, Bach2 and IRF4 quantified in B cells, ABCs and LPS-PBs. Standard deviation of three 
replicates is indicated. E) Bar graph of mRNA expression of Blimp1, Bach2 and IRF4 quantified 
in naïve B cells, GC B cells and LN-ASCs. Ubiquitin C was used as housekeeping gene to 
quantitate mRNA expression. The standard deviation of three replicates is indicated. F) Contour 
plot of cRel and Blimp1 expression in intestinal B cell and intestinal ASCs (I-ASC). G) Bar graph 
of Mean Fluorescence Intensity (MFI) of cRel and Blimp1 in B cells and I-ASCs. The mean and 
standard deviation of three replicates is shown. *p < 0.05, **p < 0.01, ***p < 0.001 and not 
significant (ns) (Unpaired Students t-test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4: Ectopic expression of cRel in BCL1 cells and generation of a Bach2-/-. A) Bar 
graph Rel mRNA expression quantified in unstimulated BCL1 (control, blank) and stimulated 
BCL1 cells (IL-2+5 24h, shaded). B) Representative immunoblot of cRel, Blimp1, Bach2 and actin 
in unstimulated (control) and stimulated BCL1 cells (IL-2+5). C) Bar graph of the percentage of 
actively cycling cells (S/G2 phase) in unstimulated BCL1 cells (control, blank) and stimulated 
BCL1 cells (IL-2+5 24h, shaded) in both BCL1 cells (gray) and BCL1-cRel cells (blue). The mean 
and standard deviation of three replicates is shown.   *p < 0.05, **p < 0.01, ***p < 0.001 and not 
significant (ns) Unpaired Students t-test). D) Immunoblot of Bach2 and actin in BCL1-cRel cells 
and Bach2-/- BCL1-cRel cells. 
  
  
 
Figure S5: ASC inhibition by cRel is robust to chosen threshold parameters. Percentage 
ASC production over time (h) in simulations with the model v1 (without cRel-Blimp1 inhibition, 
green) and v2 (with cRel-Blimp1 inhibition, grey) using the indicated thresholds of Blimp1 and AID 
to determine cell fate. The solid line indicates the mean and shaded region indicates the standard 
deviation of 3 simulations, each containing 125 founder cells. The red box indicates the threshold 
used in Figure 3B. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6: Analysis of Cas9/CRISPR-generated mutants. A) Immunoblot of Blimp1 and actin 
in BCL1 cells and Blimp1-/- BCL1 cells. The quantification of Blimp1 relative to BCL1 cells is 
indicated below.  B) Bar graph showing fold change of Rel expression in wild-type, Blimp1+/-, 
Blimp1-/- B-cells analyzed from deposited RNA-seq data generated by Tellier et al. 2016 and 
reported relative to wild-type B-cells. C) Analysis of the targeted locus in RelBS-mut BCL1 cells. 
Percentages of the total pool of sequences obtained from a population of cells (left). Cas9 binding 
sites (TGG) are indicated by an underline and target sites are indicated by a red arrow. Pie chart 
of the frequency of each sequence within the pool (right). D) and E) ChIP-qPCR for H3K9ac and 
IgG (isotype control) at the Rel (D) and Rela locus (E) in B cells (black), ABCs (green) and LPS-
PBs (blue). LPS-PBs and ABCs were generated by stimulating B cells with LPS for 72 h. H3K9ac 
and IgG (isotype control) enrichment was calculated with respect to Input. The mean and standard 
deviation of three replicates is shown. *p < 0.05, **p < 0.01, ***p < 0.001 and not significant (ns) 
(Unpaired Students t-test). F) Analysis of H3K9ac ChIP-seq data of ABCs and LPS-PBs on the 
Rel locus. The data were processed from a deposited data set by Minnich et al. 2016. 
 
  
  
 
Figure S7: Predicted ASC phenotype in cRel-/- condition is robust to chosen threshold 
parameters. Time course plot of percentage (%) increase of ASCs in cRel-deficient (cRel-/-) B 
cells compared to wild type (WT) controls as predicted by mathematical modeling using the NFB-
extended ASC differentiation model v2 and the indicated thresholds of Blimp1 and AID to 
determine cell fate.  The solid line indicates the mean and shaded region indicates the standard 
deviation of 3 replicates with 125 initial cells. The red box indicates the threshold used in Figure 
5A. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8: Kinetics of ASC generation from Rel-/- B cells. A) Flow cytometry plot of LPS-PBs 
cell percentage over time in wild type (WT) and Rel-/- B cells tracked at indicated timepoints. The 
LPS-PBs (B220low, CD138+) cell percentage is indicated in each plot. B) Bar graph of the 
percentage loss of ABCs and LPS-PBs in Rel-/- cells over WT cells at 48 h and 72 h, calculated 
Time (h)
A
24
Blimp1
0
100
200
0 36 48 60 72F
o
ld
 c
h
a
n
g
e
 (
m
R
N
A
)
Bach2
0
2
3
240 36 48 60 72
1
60
IRF4
0
5
10
15
240 36 48 72
100 102 104 106
103
104
105
0
B
2
2
0
-F
IT
C
102
101
100 102 104 106 100 102 104 106 100 102 104 106
103
104
105
0
102
101
CD138-APC
W
T
R
e
l-
/-
C D
E
-103
100
0
104
105
-103 103 104 1050 -103 103 104 1050
ABC LPS-PB
7.6% 2.7%
P
ro
p
id
iu
m
Io
d
id
e
Annexin V Alexa 488
A B C  v s  A S C  %  lo s s
%
 
C
e
l
l
 
l
o
s
s
 
i
n
 
c
R
e
l
-
/
-
%
 A
B
C
 l
o
s
s
 i
n
 c
R
e
l-
/ -
%
 A
S
C
 l
o
s
s
 i
n
 c
R
e
l -
/ -
8 0
8 5
9 0
9 5
1 0 0
4 8  h
7 2  h
**
n s
48 h         72 h                48 h         72 h
ABC                                  LPS-PB
90.7 
± 1.1
86.4 
± 3.7
88.2 
± 1.6
96.5 
± 0.8
%
 C
e
ll 
lo
s
s
 i
n
 R
e
l-
/-
80
85
90
95
10
48 72 4  h 7  h
BC LPS- B
B
LPS-PBABC
WT Rel-/- WT Rel-/-
***
***
2 X
2 X
0
5
10
15
20
%
 A
p
o
p
to
ti
c
 C
e
ll
88.2 
1.6±
96.5
± .8
90.7
± .1
86.4
±3.
as: ([𝑊𝑇 𝐴𝑆𝐶 𝑐𝑜𝑢𝑛𝑡] – [𝑅𝑒𝑙 −/− 𝐴𝑆𝐶 𝑐𝑜𝑢𝑛𝑡]) [𝑊𝑇 𝐴𝑆𝐶 𝑐𝑜𝑢𝑛𝑡])⁄   and 
([𝑊𝑇 𝐴𝐵𝐶 𝑐𝑜𝑢𝑛𝑡] – [𝑅𝑒𝑙 −/− 𝐴𝐵𝐶 𝑐𝑜𝑢𝑛𝑡]) [𝑊𝑇 𝐴𝐵𝐶 𝑐𝑜𝑢𝑛𝑡]⁄ ). Percentage cell loss is indicated in 
each graph. C) Representative flow cytometry plot of the percentage of apoptotic cells (Annexin 
V+PI- cell) in wild type ABCs and LPS-PBs at 72 h. The percentage of apoptotic cells indicated in 
each plot. D) Bar graph showing the percentage of apoptotic cells within WT-ABCs, cRel-/--ABCs, 
WT- LPS-PBs and Rel-/--LPS-PBs at 72 h. The fold change of apoptotic cells between WT (black) 
and Rel-/- (red) is indicated.  E) Bar graphs of Blimp1, Bach2, and IRF4 mRNA expression 
quantified in WT (black) and Rel-/- (red) B cells at 0 h, 24 h, 36 h, 48 h, 60 h and 72 h following 
stimulation with LPS. The mean and standard deviation of three replicates is indicated. *p < 0.05, 
**p < 0.01, ***p < 0.001 and not significant (ns) (Unpaired Students t-test). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure S9: Simulation of Rela dynamics and prediction of B cell population dynamics upon 
perturbation of Blimp1. A) Line plots of average RelA activity (nuclear RelA:p50 concentration) 
within 200 simulated lineages. Each line represents the average concentration of progeny from a 
single founder cell. ASC generating lineages are indicated as ABCs (blue) transition to 
Blimp1highAIDhigh (pink) and ASCs (red).  X-axis indicates time (h) and Y-axis indicates simulated 
nuclear RelA:p50 heterodimer concentrations (nM). B) Line graph of the proportion of cells that 
will divide at least once among ASCs relative to the proportion of cells dividing among ABCs over 
time (h). A value of 1 indicates the same number of dividing cells among ABCs and ASCs, while 
<1 indicates ASCs are less likely to divide than ABCs. C) Stacked area plot of B cell count in WT 
(black), Blimp1+/- (maroon), Blimp1-/- (red) simulations over time (h). Each simulation contained 
125 founder cells. 
 
 
 
 
 
 
 
  
 
 
 
Table S1: Regulatory network connections in the model 
 
 
Regulatory Connection Source 
IRF4 Promotes Blimp-1 Sciammas et al. 2011 MSB 
Blimp-1 Promotes IRF4 Sciammas et al. 2011 MSB 
Blimp-1 Inhibits Pax5 Sciammas et al. 2011 MSB 
IRF4 Inhibits Bach2 Sciammas et al. 2011 MSB 
IRF4 Promotes AID Sciammas et al. 2011 MSB 
Blimp-1 Inhibits Bach2 Sciammas et al. 2011 MSB 
Bach2 Inhibits Blimp-1 Sciammas et al. 2011 MSB 
Pax5 Promotes Bach2 Sciammas et al. 2011 MSB 
Pax5 Promotes AID Sciammas et al. 2011 MSB 
RelA Promotes IRF4 Siato et al. 2007 Cancer Cell 
cRel Promotes IRF4 Grumont et al. 2000 J Exp Med 
cRel Promotes Bach2 Hunter et al. 2016 Oncogene 
RelA Promotes Blimp-1 Morgan et al. 2009 Mol Cell Biol. 
cRel Promotes AID Park et al. 2009 Nat Immunol 
RelA Promotes AID Park et al. 2009 Nat Immunol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2: Parameter values in the model 
 
 
  Param Value Justification 
IRF-4 
Act 
𝑘𝑎𝐼 7.5 
Sciammas et al. 2011 
MSB 
𝑛𝑎𝐼 2 
𝐾𝑎𝐼 1 
Deg 𝑑𝐼 1 
BLIMP-1 
Act 
𝑘𝑎𝐵 7.5 
Sciammas et al. 2011 
MSB 𝑛𝑎𝐵 2 
𝐾𝑎𝐵 3 Increased from published 
value of 1 to enable 
sensitivity to RelA and 
IRF-4 
Rep 
𝐾𝑟𝐵 1 
Sciammas et al. 2011 
MSB  
𝑛𝑟𝐵 2 
Deg 𝑑𝐵 1 
Pax5 
Basal 𝑒𝑃 2 
Sciammas et al. 2011 
MSB 
Rep 
𝐾𝑟𝑃 1 
𝑛𝑟𝑃 2 
Deg d𝑃 1 
Bach2 
Act 
𝑘𝑎𝐻 7.5 
Sciammas et al. 2011 
MSB 
𝑛𝑎𝐻 1 
𝐾𝑎𝐻 1 
Rep 
𝐾𝑟𝐻  1 
𝑛𝑟𝐻 2 
Deg d𝐻 1 
AID 
Act 
𝒌𝒂𝑨 0.375 Half published value of 
0.75 to allow for activation 
by RelA and cRel. 
𝑛𝑎𝐴 1 
Sciammas et al. 2011 
MSB 
𝐾𝑎𝐴 1 
Deg 𝑑𝐴 0.1 
cRel 
Basal ?̅?𝐶 1 
Chosen to replicated 
modeling strategy of 
Sciammas et al. 2011 
MSB 
Rep 
𝐾𝑟𝐶 1 
𝑛𝑟𝐶 2 
Deg 𝑑𝐶 0.1 
RelA 
Basal 𝑒𝑅 1 
Chosen to replicated 
modeling strategy of 
Sciammas et al. 2011 
MSB 
Act 
𝑘𝑎𝑅 0.75 
𝐾𝑎𝑅 1 
𝑛𝑎𝑅 2 
Deg 𝑑R 0.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3: Sequences of primers 
 
mRNA qPCR primers 
RelA GCAGTATCCATAGCTTCCAG 
TGCTCCTCTATAGGAACGTG 
cRel TTGCAGAGATGGATACTATGAAGC 
CACCGAATACCCAAATTTTGAA 
Blimp1 GGCTCCACTACCCTTATCCTG 
TTTGGGTTGCTTTCCGTTT 
Bach2 CAGTGAGTCGTGTCCTGTGC 
TTCCTGGGAAGGTCTGTGAT 
IRF4 ATTCCAGGTGACTCTGTGCT 
TGGAGTGGTAACGTGTTCAG 
Ubiqutin C  GCCCAGTGTTACCACCAAGA 
CCCATCACACCCAAGAACA 
ChIP qPCR primers 
cRel TGAAACACCCCAGTTTCCTT 
CAGGACGCTGACCCTTATCT 
RelA TCTGGCGAATGGCTTTACTT 
CAGAAAGGGGCGGAAGAC 
 
  
Equation S1 
 
Equations of the Mathematical Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
𝑑[𝐵𝐿𝐼𝑀𝑃]
𝑑𝑡
= 
(
𝑘𝑎𝐵 ∙ [𝐼𝑅𝐹]
𝑛𝑎𝐵  
𝐾𝑎𝐵
𝑛𝑎𝐵 + [𝐼𝑅𝐹]𝑛𝑎𝐵
+
𝑘𝑎𝐵 ∙ [𝑅𝑒𝑙𝐴]
𝑛𝑎𝐵  
𝐾𝑎𝐵
𝑛𝑎𝐵 + [𝑅𝑒𝑙𝐴]𝑛𝑎𝐵
) ∙ (
𝐾𝑟𝐵
𝑛𝑟𝐵  
𝐾𝑟𝐵
𝑛𝑟𝐵 + [Bach2]𝑛𝑟𝐵
) − 𝑑𝐵 ∙ [BLIMP] 
𝑑[𝑃𝑎𝑥]
𝑑𝑡
= 
𝑒𝑃 ∙ (
𝐾𝑟𝑃
𝑛𝑟𝑃  
𝐾𝑟𝑃
𝑛𝑟𝑃 + [𝐵𝐿𝐼𝑀𝑃]𝑛𝑟𝑃
) − d𝑃 ∙ [Pax] 
𝑑[𝐼𝑅𝐹]
𝑑𝑡
= 
(𝑒𝑃 +
𝑘𝑎𝐼
3 ∙ [𝐵𝐿𝐼𝑀𝑃]
𝑛𝑎𝐼  
𝐾𝑎𝐼
𝑛𝑎𝐼 + [𝐵𝐿𝐼𝑀𝑃]𝑛𝑎𝐼
+
𝑘𝑎𝐼
40 ∙ [𝑐𝑅𝑒𝑙]
𝑛𝑎𝐼  
𝐾𝑎𝐼
𝑛𝑎𝐼 + [𝑐𝑅𝑒𝑙]𝑛𝑎𝐼
+
𝑘𝑎𝐼
40 ∙ [𝑅𝑒𝑙𝐴]
𝑛𝑎𝐼  
𝐾𝑎𝐼
𝑛𝑎𝐼 + [𝑅𝑒𝑙𝐴]𝑛𝑎𝐼
) −  𝑑𝐼 ∙ [IRF] 
𝑑[Bach2]
𝑑𝑡
= 
(
𝑘𝑎𝐻 ∙ [𝑃𝑎𝑥]
𝑛𝑎𝐻  
𝐾𝑎𝐻
𝑛𝑎𝐻 + [𝑃𝑎𝑥]𝑛𝑎𝐻
+
𝑘𝑎𝐻 ∙ [𝑐𝑅𝑒𝑙]
𝑛𝑎𝐻  
𝐾𝑎𝐻
𝑛𝑎𝐻 + [𝑐𝑅𝑒𝑙]𝑛𝑎𝐻
) ∙ (
𝐾𝑟𝐻
𝑛𝑟𝐻  
𝐾𝑟𝐻
𝑛𝑟𝐻 + [𝐵𝐿𝐼𝑀𝑃]𝑛𝑟𝐻 + [𝐼𝑅𝐹]𝑛𝑟𝐻
) − d𝐻 ∙ [Bach2] 
𝑑[𝐴𝐼𝐷]
𝑑𝑡
= 
(
𝑘𝑎𝐴 ∙ ([𝐼𝑅𝐹] ∙ [𝑃𝑎𝑥]
2)𝑛𝑎𝐴  
𝐾𝑎𝐴
𝑛𝑎𝐴 + ([𝐼𝑅𝐹] ∙ [𝑃𝑎𝑥]2)𝑛𝑎𝐴
+
𝑘𝑎𝐴 ∙ [𝑐𝑅𝑒𝑙]
𝑛𝑎𝐴  
𝐾𝑎𝐴
𝑛𝑎𝐴 + [𝑐𝑅𝑒𝑙]𝑛𝑎𝐴
+
𝑘𝑎𝐴 ∙ [𝑅𝑒𝑙𝐴]
𝑛𝑎𝐴  
𝐾𝑎𝐴
𝑛𝑎𝐴 + [𝑅𝑒𝑙𝐴]𝑛𝑎𝐴
) − 𝑑𝐴 ∙ [AID] 
𝑑[𝑐𝑅𝑒𝑙]
𝑑𝑡
= 𝑒𝐶 − 𝑑𝐶 ∙ [cRel] 
𝑑[𝑅𝑒𝑙𝐴]
𝑑𝑡
= 𝑒𝑅 − 𝑑𝑅 ∙ [RelA] 
